Free tool
FAERS Monitor: Activase
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 103172 or its brand name (Activase, Alteplase). Reports on generic versions are filed under their own applications.
Reports
15,039
Serious
10,406
69% of reports
Hospitalization
3,091
Death reported
3,242
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- no adverse event2,541
- off label use1,883
- death1,194
- gingival bleeding1,031
- cerebral haemorrhage827
- haemorrhage intracranial741
- drug ineffective646
- angioedema631
- haemorrhage577
- haemorrhagic transformation stroke441
- product storage error391
- nausea372
- dyspnoea349
- hypotension347
- vomiting345
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 68 |
| 2005 | 64 |
| 2006 | 64 |
| 2007 | 95 |
| 2008 | 137 |
| 2009 | 241 |
| 2010 | 138 |
| 2011 | 201 |
| 2012 | 1,027 |
| 2013 | 926 |
| 2014 | 422 |
| 2015 | 399 |
| 2016 | 897 |
| 2017 | 1,847 |
| 2018 | 850 |
| 2019 | 395 |
| 2020 | 711 |
| 2021 | 868 |
| 2022 | 1,039 |
| 2023 | 799 |
| 2024 | 2,836 |
| 2025 | 604 |
| 2026 | 411 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,039,120 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| haemorrhagic transformation strokeSignal | 441 | 578.7 | 518.6 | 179,520 |
| gingival bleedingSignal | 1,031 | 114.1 | 107.3 | 106,841 |
| haemorrhage intracranialSignal | 741 | 72.9 | 67.8 | 49,894 |
| cerebral haemorrhageSignal | 827 | 33.0 | 30.9 | 25,121 |
| angioedemaSignal | 631 | 20.2 | 18.7 | 11,371 |
| no adverse eventSignal | 2,541 | 19.9 | 19.2 | 45,290 |
| haemorrhageSignal | 577 | 7.8 | 7.2 | 3,388 |
| product storage errorSignal | 391 | 6.3 | 5.7 | 1,726 |
| off label useSignal | 1,883 | 3.0 | 2.9 | 2,633 |
| hypotensionSignal | 347 | 2.4 | 2.2 | 290 |
| death | 1,194 | 1.9 | 1.8 | 565 |
| vomiting | 345 | 1.0 | 0.9 | 0 |
| dyspnoea | 349 | 0.9 | 0.8 | 8 |
| drug ineffective | 646 | 0.7 | 0.6 | 99 |
| nausea | 372 | 0.7 | 0.6 | 69 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.